Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Ebert

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Theranostics|April 22, 2015
Characterization of magnetic viral complexes for targeted delivery in oncologyIsabella Almstätter, Olga Mykhaylyk, Marcus Settles, et al.
EMBO Molecular Medicine|July 16, 2013
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescenceVeronika Hampl, Claudia Martin, Achim Aigner, et al.
Journal of Virology|April 1, 2011
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropismAlexander Muik, Inna Kneiske, Marina Werbizki, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2013
Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosisJennifer Altomonte, Sabrina Marozin, Enrico N De Toni, et al.
Human Gene Therapy|June 7, 2008
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapyLan Wu, Tian-gui Huang, Marcia Meseck, et al.
Plos One|June 12, 2010
Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinomaSabrina Marozin, Enrico N De Toni, Antonia Rizzani, et al.
Journal of Virology|February 21, 2012
Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125Sabrina Marozin, Jennifer Altomonte, Sibylle Apfel, et al.
Journal of Virology|September 21, 2018
A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular CarcinomaSarah Abdullahi, Melanie Jäkel, Sabine J Behrend, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|April 22, 2022
Diabetes and Road TrafficOliver Ebert, Barbara Bohn, Bernd Bertram, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|December 21, 2019
Diabetes and Road TrafficOliver Ebert, Barbara Bohn, Bernd Bertram, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Theranostics|April 22, 2015
Characterization of magnetic viral complexes for targeted delivery in oncologyIsabella Almstätter, Olga Mykhaylyk, Marcus Settles, et al.
EMBO Molecular Medicine|July 16, 2013
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescenceVeronika Hampl, Claudia Martin, Achim Aigner, et al.
Journal of Virology|April 1, 2011
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropismAlexander Muik, Inna Kneiske, Marina Werbizki, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2013
Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosisJennifer Altomonte, Sabrina Marozin, Enrico N De Toni, et al.
Human Gene Therapy|June 7, 2008
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapyLan Wu, Tian-gui Huang, Marcia Meseck, et al.
Plos One|June 12, 2010
Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinomaSabrina Marozin, Enrico N De Toni, Antonia Rizzani, et al.
Journal of Virology|February 21, 2012
Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125Sabrina Marozin, Jennifer Altomonte, Sibylle Apfel, et al.
Journal of Virology|September 21, 2018
A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular CarcinomaSarah Abdullahi, Melanie Jäkel, Sabine J Behrend, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|April 22, 2022
Diabetes and Road TrafficOliver Ebert, Barbara Bohn, Bernd Bertram, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|December 21, 2019
Diabetes and Road TrafficOliver Ebert, Barbara Bohn, Bernd Bertram, et al.
Pageof 5